STOCK TITAN

Treace to Present at Stifel 2023 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on November 14, 2023. The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure. A live webcast and replay will be available on the investor relations website.
Positive
  • None.
Negative
  • None.

PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, beginning at approximately 8:35 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/.

Internet Posting of Information

Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients, and the Hammertoe PEEK Fixation System, designed to address hammertoe, claw toe and mallet toe deformities. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Contacts:

Treace Medical Concepts
Julie Dewey, IRC
Chief Communications & Investor Relations Officer
jddewey@treace.com | 209-613-6945


Treace will participate in the Stifel 2023 Healthcare Conference.

The fireside chat will take place on Tuesday, November 14, 2023, at approximately 8:35 am ET.

The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure.

A live webcast and replay of the fireside chat will be available on the Company's investor relations website at https://investors.treace.com/.

Investors can find important information about Treace on the company's website at www.treace.com.
Treace Medical Concepts Inc

NASDAQ:TMCI

TMCI Rankings

TMCI Latest News

TMCI Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Ponte Vedra

About TMCI

treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.